Company Description
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia.
It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.
In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s disease.
Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3.
It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,100 |
| CEO | Yvonne Greenstreet |
Contact Details
Address: 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 United States | |
| Phone | 617 551 8200 |
| Website | alnylam.com |
Stock Details
| Ticker Symbol | ALNY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178670 |
| CUSIP Number | 02043Q107 |
| ISIN Number | US02043Q1076 |
| Employer ID | 77-0602661 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | Chief Executive Officer and Director |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board and Independent Director |
| Jeffrey V. Poulton M.B.A. | Chief Financial Officer and Executive Vice President |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive Vice President, Chief Scientific Officer and Head of Early Research and Early Development |
| Dr. Pushkal P. Garg M.D. | Chief Medical Officer and Executive Vice President of Development and Medical Affairs |
| Tolga Tanguler M.B.A. | Executive Vice President and Chief Commercial Officer |
| Timothy J. Maines | Chief Technical Operations and Quality Officer |
| Piyush Sharma J.D. | Chief Ethics and Compliance Officer |
| Robert W. Hesslein Esq., J.D. | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Christine Regan Lindenboom | Chief Corporate Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2025 | SCHEDULE 13G/A | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 24, 2025 | ARS | Filing |
| Mar 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 24, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2025 | 144 | Filing |
| Mar 24, 2025 | 144 | Filing |
| Mar 21, 2025 | 144 | Filing |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 14, 2025 | PRE 14A | Other preliminary proxy statements |